ABSTRACT: The X-ray structure of the previously reported PPARδ modulator 1 bound to the ligand binding domain (LBD) revealed that the amide moiety in 1 exists in the thermodynamically disfavored cis-amide orientation. Isosteric replacement of the cis-amide with five-membered heterocycles led to the identification of imidazole 17 (MA-0204), a potent, selective PPARδ modulator with good pharmacokinetic properties. MA-0204 was tested in vivo in mice and in vitro in patientderived muscle myoblasts (from Duchenne Muscular Dystrophy (DMD) patients); 17 altered the expression of PPARδ target genes and improved fatty acid oxidation, which supports the therapeutic hypothesis for the study of MA-0204 in DMD patients.
D
uchenne Muscular Dystrophy (DMD) is an X-linked recessive genetic disease involving severe muscle wasting that results from cycles of muscle degeneration/regeneration. 1, 2 DMD patients carry mutations in the DMD gene, which encodes for dystrophin, a cellular protein scaffold that is critical for muscle membrane integrity. 3 In addition to weakened structural integrity, DMD is also characterized by mitochondrial impairment with evidence of decreased fatty acid oxidative phosphorylation. 4−7 In skeletal muscle, PPARδ elicits a transcriptional cascade resulting in increased fatty acid oxidation while sparing glucose utilization, which enables muscle to function for a longer duration without decreasing systemic glucose levels or increasing muscle lactic acid. 8 We hypothesized that engaging the PPARδ transcriptional cascade with a selective PPARδ modulator would provide functional improvements to DMD muscle.
The selectivity for PPARδ is considered to be crucial to mitigate the undesirable effects (such as hepatotoxicity, myopathy, edema, cardiac toxicity, etc.) observed with some modulators of PPARα (fibrates), PPARγ (thiazolidinediones), and dual PPARα/γ (e.g., Muraglitazar) in clinical and/or preclinical studies, 9,10 while GW501516, 11 a known PPARδ modulator, has shown tumorogenic effects in mice. 12 As per the company Web sites, two modulators of PPARδ, Seladelpar and Elafibranor, have cleared the two-year carcinogenicity studies in rats. This suggests that tumorogenic potential is not a class effect for the PPAR modulators.
We recently disclosed the potent and selective PPARδ modulator 1 (Figure 1 ), which displayed significantly improved pharmacokinetic properties relative to previously reported compounds.
13−15 The X-ray structure of 1 bound to the ligand binding domain (LBD) of the PPARδ receptor revealed that the carbonyl oxygen and the N-methyl group are in a cis relationship. 13 A trans-amide has been reported to be thermodynamically favored over a cis-amide. 16 cis-Amides are uncommon even in the peptide literature, especially for amino acids other than proline. 17 Molecular mechanics-based energy minimization and conformational analysis of 1 predicted that the trans isomer is favored by 1.3 kcal/mol over the cis isomer.
18 Therefore, we reasoned that a molecule in a "locked cis-amide" conformation would improve binding affinity for PPARδ. Herein, we disclose a series of compounds represented by general structure 2, where five-membered heterocyclic rings ( Figure 1 ) serve as isosteric replacements of the cis-amide bond.
The heterocyclic cores required for compounds 2a−g were synthesized using known synthetic procedures (see Supporting Information for the detailed procedures). Synthesis of 2g is shown in Scheme 1 as a representative example.
PPARδ, PPARα, and PPARγ activities of these compounds were assessed using transactivation assays. 19 All the compounds were screened for exposure in mice following an intravenous dose of 3 mg/kg. The results are shown in Table 1 .
All of the heterocyclic compounds (except compound 2f) in Table 1 show greater affinity (EC 50 <10 nM) for PPARδ receptor than the original amide lead 1, supporting our hypothesis regarding the use of heterocycles as cis-amide isosteres. All the compounds were found to selectively activate PPARδ (>1000-fold less potent for PPARα and PPARγ receptors). Unlike compound 1, all the compounds (except 2b) shown in Table 1 have plasma clearances that exceed hepatic blood flow in mice (>85 mL/min/kg), short half-lives (<1 h), and low plasma exposures (AUC <1000 ng·h/mL) when dosed intravenously in mice. Compound 2b has the highest plasma exposure among the compounds shown in Table 1 but is 5−10-fold less potent for PPARδ compared to the remaining compounds. Although 2d and 2g showed comparable PPARδ activity and plasma clearance values, imidazole 2g was selected for further optimization based on the superior solubility properties (data not shown). Our previous work in the benzamide series (like compound 1) demonstrated that modifications of the hexanoic acid side chain significantly influence the observed pharmacokinetic (PK) properties. 13, 14 Therefore, similar chemistry exploration was undertaken in the imidazole series (e.g., 2g). Compounds 13−22 were synthesized as shown in Scheme 2. The results of pharmacological and pharmacokinetic studies are summarized in Table 2 .
In general, PPARδ activity was significantly better for imidazole series of compounds (e.g., PPARδ EC 50 = 37 nM for 1 compared to PPARδ EC 50 = 1 nM for 2g). However, higher plasma exposures were observed for the compounds in the benzamide series compared to the imidazole series (e.g., AUC = 3300 ng·h/mL for 1 compared to 300 ng·h/mL for 2g). A significant improvement in plasma clearance and plasma exposures was observed when the hexanoic acid region included substitutions at α, β, and γ positions relative to the carboxylic acid (e.g., 2g, 14, and 15 compared to 13). A similar trend in the pharmacokinetic properties was observed for the benzamide series of compounds.
Among the substituents tried as a replacement of the 2-furyl moiety (compounds 17−22), 4-trifluoromethoxy group containing compound 17 stood out based on subnanomolar activity for PPARδ, good selectivity over the other PPAR subtypes, reduced plasma clearance, and improved plasma exposure.
An X-ray structure of compound 13 bound to the LBD of PPARδ (Figure 2 ) was obtained at 2 Å resolution. 21 As anticipated, the imidazole ring in 13 superimposes nicely with the cis-amide bond in the protein bound X-ray structure of 1. Almost all the interactions observed between 1 and the protein (His287, His413, Thr253, and Tyr437) are conserved in the X-ray structure for 13. One of the nitrogen atoms in the imidazole ring of 13 forms a water-mediated interaction with Leu304 as was observed for the cis-amide in the X-ray structure for 1.
13
The binding interactions with Val312 and Ile328 have been postulated to impart selectivity for a known PPARδ selective modulator, GW0742. 22 Overlay of the crystal structures of 13 with GW0742 (PDB ID: 3TKM) reveals a significant downward movement of the Ile328 residue in the structure for 13, even though the Val312 conformation is conserved in both structures. This movement is possibly necessitated by the presence of the benzyl moiety on the imidazole ring. Ile328 in PPARδ is replaced by methionine residues in PPARα and PPARγ. Changes in the Ile328 region and the watermediated interaction with Leu304 potentially contribute to the improved PPARδ selectivity for the imidazole series of compounds.
Compound 17 was profiled in multiple in vitro and in vivo assays (Table 3 ). Compound 17 is >10 000-fold selective for activation of PPARδ over PPARα and PPARγ receptors. The PPARδ potency was 10-fold less for mouse and rat PPARδ receptors than for the human PPARδ receptor; this effect is well documented for PPAR modulators. 11 Compound 17 is selective (EC 50 >10 μM) over other nuclear receptors, for example:
androgen, progesterone, and glucocorticoid receptors. Compound 17 is also inactive in a panel of 68 receptors and transporters that are known to pose safety-related challenges in the clinic. Compound 17 exhibits high protein binding to mouse plasma, good permeability, and low potential for efflux. Compound 17 did not show mutagenic potential or inhibit major cytochrome P450 enzymes (IC 50 ≥10 μM). Compound 17 has acceptable PK profiles in mice and rats upon oral dosing. 23 In the aggregate, these properties made 17 (MA-0204) an excellent candidate for study in pharmacological assays.
For compound 17 (MA-0204) to be considered as a potential treatment for Duchene Muscular Dystrophy (DMD), it was necessary to demonstrate that it met at least three criteria: (1) elicit a response in the target tissue, i.e., skeletal muscle, (2) affect changes in the PPARδ-responsive genes in DMD patient myoblasts, and (3) affect beta oxidation of fatty acid in patient myoblasts. The results from these in vivo and ex vivo experiments are described below.
To determine if 17 was capable of eliciting a biological effect in skeletal muscle, mice were dosed orally with MA-0204 and GW501516, and target gene expression was assessed by qPCR (quantitative polymerase chain reaction). As shown in Figure 3 , 17 increased PPARδ target gene transcription in the muscle, represented here by Pdk4 (pyruvate dehydrogenase kinase 4).
In order to test for changes in fatty acid oxidation, primary myoblasts isolated from a 17-month-old DMD patient were utilized. Compound 17 increased PPARδ target genes ANGPTL4 (angiopoietin like protein 4), CPT1a (carnitine palmytoyltransferase 1a), and PDK4 in a dose-dependent manner (Figure 4) . Furthermore, oxidation of the long-chain fatty acid palmitic acid was significantly elevated at the concentrations of 1.2, 4, and 12 nM (3-, 10-, and 30-fold EC 50 , respectively), which represents a functional improvement of up to 52% in palmitate utilization ( Figure 5 ).
In summary, we have reported the design and synthesis of a series of potent and selective PPARδ modulators by utilizing X-ray crystallographic information derived from previously disclosed compounds. The key compound to emerge from these studies, 17 (MA-0204), combined potency and PK properties, which enabled the demonstration that selective PPARδ 19 In selected cases, compounds were also assayed in a protein interaction assay. 20 Both assays were in good agreement. EC 50 values are an average of at least two experiments (SEM shown unless single determination).
b All the compounds, except 2d, showed EC 50 >10 000 nM for PPARγ; PPARγ EC 50 for 2d = 5530 nM; 
)
A to B = 36; B to A = 41 (efflux ratio 1.2) CYP450 inhibition >10 μM for CYPs except 2C9 (56% inhibition @ 10 μM) mutagenicity nonmutagenic in mini-Ames test mouse PK d 1 mg/kg IV: t 1/2 = 2.7 h; CL = 33 mL/min/kg; Vss = 5.8 L/kg; AUC = 503 ng·h/mL 3 mg/kg PO: t 1/2 = 3.4 h; C max = 510 ng/mL; AUC = 630 ng·h/mL; %F = 42 rat PK e 1 mg/kg IV: t 1/2 = 6.1 h ; Vss = 1.8 L/kg; CL = 10 mL/min/kg; AUC = 1590 ng·h/mL 3 mg/kg PO: t 1/2 = 4.6 h; C max = 1,089 ng/mL; AUC = 4920 ng·h/mL; %F = 90 monkey PK f 3 mg/kg IV: t 1/2 = 6.1 h; CL = 0.4 mL/min/kg; Vss = 3.2 L/kg ; AUC = 8400 ng·h/mL 10 mg/kg PO: t 1/2 = 7.3 h: C max = 1660 ng/mL; AUC = 3840 ng·h/mL; %F = 13 a Transactivation assay. 
